Table 4.
Sex hormone levels in patients aged 50 years and over, stratified by sex and outcome.
| Sex hormones median (IQR) | Female* (n=52) | Male# (n=68) | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Testosterone nmol/L | Estradiol pg/mL | Progesterone ng/mL | DHEA microg/L | Testosterone nmol/L | Estradiol pg/mL | Progesterone ng/mL | DHEA microg/L | ||
| Normality range | 0.43-1.24 | <10-28 | <0.1-0.2 | 29.7-282.9 | 7.7-24.8 | 11-44 | <0.1-0.2 | 48.6-447.6 | |
| ARDS (119/120) | |||||||||
| NO | 0.9 (0.7-1.6) | 26 (15-41) | 0.1 (0.1-0.2) | 66.0 (44.8-106.9) | 5.3 (1.8-11.1) | 24 (19.5-33.0) | 0.1 (0.1-0.2) | 69.3 (32.5-96.2) | |
| YES | 0.9 (0.6-1.1) | 18.5 (10-21) | 0.2 (0.1-0.3) | 61.2 (30.3-79.1) | 3.6 (1.3-6.2) | 31 (23.0-40.0) | 0.1 (0.1-0.2) | 69.4 (50.7-118.3) | |
| p-value | 0.2182 | 0.0459 | 0.2038 | 0.2740 | 0.0378 | 0.1270 | 0.9008 | 1 | |
| Severe COVID-19 | |||||||||
| NO | 0.7 (0.6-4.7) | 18 (10-31) | 0.1 (0.1-0.2) | 86.5 (52.9-105.4) | 8.5 (5.9-12.4) | 23.5 (16.5-27.5) | 0.2 (0.1-0.3) | 67.1 (23.1-171.5) | |
| YES | 0.9 (0.7-1.3) | 20 (14-35) | 0.2 (0.1-0.3) | 63.7 (38.2-103.25) | 3.7 (1.3-6.3) | 30.0 (22.0-41.5) | 0.1 (0.1-0.2) | 69.4 (50.7-100.1) | |
| p-value | 0.9911 | 0.4187 | 0.1092 | 0.4707 | 0.0011 | 0.3146 | 0.0176 | 0.8905 | |
| In-hospital mortality | |||||||||
| NO | 0.8 (0.6-1.3) | 20 (15-30) | 0.1 (0.1-0.2) | 69.0 (40.8-105.4) | 4.8 (1.5-7.9) | 24.0 (20.0-33.0) | 0.1 (0.1-0.2) | 76.6 (42.3-117.2) | |
| YES | 1.2 (1.0-1.7) | 36 (11-64) | 0.2 (0.1-0.4) | 61.4 (48.8-96.4) | 2.4 (1.3-4.6) | 40.0 (30.0-52.0) | 0.2 (0.1-0.2) | 62.6 (32.5-91.9) | |
| p-value | 0.1418 | 0.4520 | 0.4231 | 0.7376 | 0.0536 | 0.0006 | 0.1618 | 0.6029 | |
*Female: 18/52 ARDS; 41/52 severe COVID-19, 13/52 in hospital mortality.
#Male: 35/68 ARDS; 56/68 severe COVID-19, 15/68 in hospital mortality.